Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1934 1
1951 1
1953 4
1954 2
1955 3
1956 3
1957 4
1958 1
1960 2
1961 14
1962 19
1963 19
1964 28
1965 9
1966 32
1967 31
1968 47
1969 46
1970 35
1971 38
1972 29
1973 28
1974 40
1975 44
1976 51
1977 57
1978 37
1979 35
1980 38
1981 54
1982 87
1983 95
1984 96
1985 111
1986 118
1987 133
1988 133
1989 132
1990 140
1991 126
1992 109
1993 111
1994 113
1995 106
1996 121
1997 120
1998 149
1999 164
2000 164
2001 173
2002 178
2003 190
2004 179
2005 198
2006 211
2007 232
2008 229
2009 282
2010 305
2011 311
2012 294
2013 382
2014 393
2015 377
2016 359
2017 387
2018 419
2019 395
2020 359
Text availability
Article attribute
Article type
Publication date

Search Results

8,218 results
Results by year
Filters applied: . Clear all
Page 1
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, Yen CC, Kubota Y, Kim SB, Hsu CH, Holtved E, Xynos I, Kodani M, Kitagawa Y. Kato K, et al. Lancet Oncol. 2019 Nov;20(11):1506-1517. doi: 10.1016/S1470-2045(19)30626-6. Epub 2019 Sep 30. Lancet Oncol. 2019. PMID: 31582355 Clinical Trial.
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4).
Boku N, Ryu MH, Kato K, Chung HC, Minashi K, Lee KW, Cho H, Kang WK, Komatsu Y, Tsuda M, Yamaguchi K, Hara H, Fumita S, Azuma M, Chen LT, Kang YK. Boku N, et al. Among authors: kato k. Ann Oncol. 2019 Feb 1;30(2):250-258. doi: 10.1093/annonc/mdy540. Ann Oncol. 2019. PMID: 30566590 Free PMC article. Clinical Trial.
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data.
Chen LT, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Sameshima H, Kang YK, Boku N. Chen LT, et al. Among authors: kato k. Gastric Cancer. 2020 May;23(3):510-519. doi: 10.1007/s10120-019-01034-7. Epub 2019 Dec 20. Gastric Cancer. 2020. PMID: 31863227 Free PMC article.
Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
Masuda K, Shoji H, Nagashima K, Yamamoto S, Ishikawa M, Imazeki H, Aoki M, Miyamoto T, Hirano H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Boku N. Masuda K, et al. Among authors: kato k. BMC Cancer. 2019 Oct 21;19(1):974. doi: 10.1186/s12885-019-6150-y. BMC Cancer. 2019. PMID: 31638948 Free PMC article.
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer.
Satoh T, Kang YK, Chao Y, Ryu MH, Kato K, Cheol Chung H, Chen JS, Muro K, Ki Kang W, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Tanimoto M, Chen LT, Boku N. Satoh T, et al. Among authors: kato k. Gastric Cancer. 2020 Jan;23(1):143-153. doi: 10.1007/s10120-019-00970-8. Epub 2019 May 13. Gastric Cancer. 2020. PMID: 31087200 Free PMC article. Clinical Trial.
Serum microRNA profile enables preoperative diagnosis of uterine leiomyosarcoma.
Yokoi A, Matsuzaki J, Yamamoto Y, Tate K, Yoneoka Y, Shimizu H, Uehara T, Ishikawa M, Takizawa S, Aoki Y, Kato K, Kato T, Ochiya T. Yokoi A, et al. Among authors: kato k. Cancer Sci. 2019 Dec;110(12):3718-3726. doi: 10.1111/cas.14215. Epub 2019 Nov 16. Cancer Sci. 2019. PMID: 31599471 Free PMC article.
NIST Interlaboratory Study on Glycosylation Analysis of Monoclonal Antibodies: Comparison of Results from Diverse Analytical Methods.
De Leoz MLA, Duewer DL, Fung A, Liu L, Yau HK, Potter O, Staples GO, Furuki K, Frenkel R, Hu Y, Sosic Z, Zhang P, Altmann F, Gru Nwald-Grube C, Shao C, Zaia J, Evers W, Pengelley S, Suckau D, Wiechmann A, Resemann A, Jabs W, Beck A, Froehlich JW, Huang C, Li Y, Liu Y, Sun S, Wang Y, Seo Y, An HJ, Reichardt NC, Ruiz JE, Archer-Hartmann S, Azadi P, Bell L, Lakos Z, An Y, Cipollo JF, Pucic-Bakovic M, Štambuk J, Lauc G, Li X, Wang PG, Bock A, Hennig R, Rapp E, Creskey M, Cyr TD, Nakano M, Sugiyama T, Leung PA, Link-Lenczowski P, Jaworek J, Yang S, Zhang H, Kelly T, Klapoetke S, Cao R, Kim JY, Lee HK, Lee JY, Yoo JS, Kim SR, Suh SK, de Haan N, Falck D, Lageveen-Kammeijer GSM, Wuhrer M, Emery RJ, Kozak RP, Liew LP, Royle L, Urbanowicz PA, Packer NH, Song X, Everest-Dass A, Lattová E, Cajic S, Alagesan K, Kolarich D, Kasali T, Lindo V, Chen Y, Goswami K, Gau B, Amunugama R, Jones R, Stroop CJM, Kato K, Yagi H, Kondo S, Yuen CT, Harazono A, Shi X, Magnelli PE, Kasper BT, Mahal L, Harvey DJ, O'Flaherty R, Rudd PM, Saldova R, Hecht ES, Muddiman DC, Kang J, Bhoskar P, Menard D, Saati A, Merle C, Mast S, Tep S, Truong J, Nishikaze T, Sekiya S, Shafer A, Funaoka S, Toyoda M, de Vreugd P, Caron C, Pradhan P, Tan NC, Mechref Y, Patil S, Rohrer JS, Chakrabarti R, Dadke D, Lahori M, Zou C, Cairo C, Reiz B, Whittal RM, Lebrilla CB, Wu L, Guttman A, Szigeti M, Kremkow BG, Lee KH, Sihlbom C, Adamczyk B, Jin C, Karlsson NG, Örnros J, Larson G, Nilsson J, Meyer B, Wiegandt A, Komatsu E, Perreault H, Bodnar ED, Said N, Francois YN, Leize-Wagner E, Maier S, Zeck A, Heck AJR, Yang Y, Haselberg R, Yu YQ, Alley W, Leone JW, Yuan H, Stein SE. De Leoz MLA, et al. Among authors: kato k. Mol Cell Proteomics. 2020 Jan;19(1):11-30. doi: 10.1074/mcp.RA119.001677. Epub 2019 Oct 7. Mol Cell Proteomics. 2020. PMID: 31591262 Free PMC article.
Cancer stem-like properties and gefitinib resistance are dependent on purine synthetic metabolism mediated by the mitochondrial enzyme MTHFD2.
Nishimura T, Nakata A, Chen X, Nishi K, Meguro-Horike M, Sasaki S, Kita K, Horike SI, Saitoh K, Kato K, Igarashi K, Murayama T, Kohno S, Takahashi C, Mukaida N, Yano S, Soga T, Tojo A, Gotoh N. Nishimura T, et al. Among authors: kato k. Oncogene. 2019 Apr;38(14):2464-2481. doi: 10.1038/s41388-018-0589-1. Epub 2018 Dec 7. Oncogene. 2019. PMID: 30532069 Free PMC article.
Monitoring of cancer patients via next-generation sequencing of patient-derived circulating tumor cells and tumor DNA.
Onidani K, Shoji H, Kakizaki T, Yoshimoto S, Okaya S, Miura N, Sekikawa S, Furuta K, Lim CT, Shibahara T, Boku N, Kato K, Honda K. Onidani K, et al. Among authors: kato k. Cancer Sci. 2019 Aug;110(8):2590-2599. doi: 10.1111/cas.14092. Epub 2019 Jul 23. Cancer Sci. 2019. PMID: 31169336 Free PMC article.
Systemic treatment of advanced esophageal squamous cell carcinoma: chemotherapy, molecular-targeting therapy and immunotherapy.
Hirano H, Kato K. Hirano H, et al. Among authors: kato k. Jpn J Clin Oncol. 2019 May 1;49(5):412-420. doi: 10.1093/jjco/hyz034. Jpn J Clin Oncol. 2019. PMID: 30920626 Review.
8,218 results
Jump to page
Feedback